
CPHI Awards Winner for Manufacturing Excellence: Anemocyte and mRNA Synthesis
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, breaks down the company’s one-pot technology for mRNA synthesis, AMCAP, which won the CPHI Award for Manufacturing Excellence at CPHI Milan 2026.
Anemocyte, a biotech manufacturing organization that specializes in the contract development and manufacturing of plasmids, won the CPHI Award for Manufacturing Excellence at CPHI Milan 2026 in October for the company’s one-pot technology for messenger RNA (mRNA) synthesis, AMCAP. PharmTech spoke with Marco Pupo, PhD, innovation and development coordinator at Anemocyte, to find out more about the technology and mRNA synthesis.
Pupo frames the innovation against a long-standing trade-off in mRNA manufacturing. Co-transcriptional capping with cap analogs offers procedural simplicity in a single-pot reaction, but the analogs account for a large share of raw material costs and can deliver suboptimal capping efficiency with certain sequences. According to Pupo, 2-step enzymatic capping using methyltransferase enzymes produces good Cap1 structures and uses inexpensive native nucleoside triphosphates (NTPs), but demands an intermediate purification or diafiltration step, higher reaction volumes, longer incubation times, and carries greater risk of product degradation across multiple handling steps.
Pupo explains that AMCAP was designed to eliminate that contrast, achieving near-100% Cap1 fidelity and the raw material economics of enzymatic chemistry while matching or exceeding the throughput and volumetric yields of one-pot reactions. Pupo identifies 3 critical parameters in a concerted one-pot reaction. Magnesium must be held within a narrow window, because T7 polymerase and the capping enzymes have different requirements and NTP consumption liberates free pyrophosphatase. Byproduct accumulation must be controlled, particularly inorganic pyrophosphate at high transcription yields, alongside adequate S-adenosylmethionine and guanosine triphosphate levels. Third, synthesis and capping kinetics must be synchronized so the nascent RNA stays in a relaxed conformation accessible to the capping enzymes.
Rather than one-factor-at-a-time screening, Anemocyte used high-throughput process development with design of experiments and in-line process analytical technology to map the interacting variables.
About the Speaker
Marco holds a background in Pharmaceutical Technology and Biochemistry, bringing over a decade of academic and industry experience in biotechnology R&D. He has successfully coordinated cross-functional teams in matrixed environments, overseeing international programs from proof-of-concept to GMP technology transfer. Marco specializes in process and analytical development for non-viral cell therapies, proteins, and nucleic acid-based therapeutics. An expert inventor in the RNA field, he has pioneered breakthrough single-pot and simultaneous co-transcriptional in vitro capping technologies (AMCAP™) to streamline scale-up and reduce manufacturing bottlenecks for therapeutic mRNA.
Related to this article









